Pomalidomide continues to show promise as a treatment for relapsed or refractory multiple myeloma patients, according to updated results from two recent Phase 2 clinical trials.

Findings from the two trials were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago earlier this month.

“Pomalidomide has been tested in multiple clinical trials … and responses were between 30 percent to up to 65 percent when patients had one to three prior lines of therapy. Most interestingly, this agent is showing responses even in patients who are [resistant to] …

Results from a number of multiple myeloma studies were presented yesterday during the second day of the American Society of Hematology (ASH) 2011 annual meeting in San Diego.

Predicting Response To Immunomodulatory Drugs

During an oral presentation and a poster presentation yesterday, researchers discussed the role of the protein cereblon in the treatment of myeloma.  Results from one study (abstract) in myeloma cell lines suggested that cereblon plays a key role in whether multiple myeloma patients respond to the immunomodulatory drugs Revlimid (lenalidomide) and pomalidomide.  Another study (abstract) …

Three myeloma experts yesterday presented additional clinical trial data on the possible link between Revlimid and secondary cancer in multiple myeloma patients.  All three experts concluded that Revlimid’s benefit as a myeloma treatment outweighs its risks.

The presentations were made at a session of the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

In a summary talk reviewing the three presentations, Dr. Ola Landgren from the U.S. National Cancer Institute noted that the risk of developing a secondary cancer following Revlimid (lenalidomide) therapy was significantly lower than a myeloma …

Yesterday was the third day of the American Society of Clinical Oncology (ASCO) 2011 annual meeting in Chicago, and it was especially packed with pre­sen­ta­tions re­lated to mul­ti­ple myeloma.

There was a morn­ing session where a total of eight re­search abstracts were pre­sented and discussed.  Then, late in the afternoon, there was an education session focused on mul­ti­ple myeloma, with sev­er­al dif­fer­en­t pre­sen­ta­tions.

The pre­sen­ta­tions during the morn­ing session were on three dif­fer­en­t topics: Revlimid (lena­lido­mide) and its po­ten­tial link to sec­ond­ary cancer; myeloma bone dis­ease; and new drugs being devel­oped as po­ten­tial …